<DOC>
	<DOCNO>NCT02094833</DOCNO>
	<brief_summary>The aim study evaluate immunogenicity safety novel DTaP-IPV-Hep B-PRP~T fully liquid combine hexavalent vaccine ( study vaccine ) administer 2 , 4 , 6 month age compare Sanofi Pasteur 's DTaP-IPV//PRP~T combine vaccine ( Pentaxim™ ) give 2 , 4 , 6 month age Hep B vaccine ( Euvax B® ) give 1 6 month age South Korean infant receive birth dose Hep B born mother document serum anti-HBs Ag negative . Primary Objective - To demonstrate non-inferiority term seroprotection ( Diphtheria , Tetanus , poliovirus type 1 , 2 , 3 , PRP-T , Hep B ) vaccine response pertussis antigen ( pertussis toxoid [ PT ] filamentous haemagglutinin [ FHA ] ) Group A versus Group B , one month third dose combine vaccine . Secondary Objectives : - To study immunogenicity two vaccination scheme , first dose one month last dose vaccine . - To study safety dose vaccine administer two vaccination scheme</brief_summary>
	<brief_title>DTaP-IPV-Hep B-PRP~T Combined Vaccine Versus DTaP-IPV//PRP~T Combined Vaccine + Hep B Vaccine Hep B Primed Infants</brief_title>
	<detailed_description>Study participant receive first dose recombinant Hep B vaccine birth receive either DTaP-IPV-Hep B-PRP~T combine vaccine 2 , 4 , 6 month age + 3 dos Hep B vaccine Hep B vaccine ( Euvax B® ) 1 6 month age DTaP IPV//PRP~T combine vaccine ( Pentaxim™ ) 2 , 4 , 6 month age , accord official vaccination schedule Hep B , DTaP , poliovirus , Hib vaccination South Korea .</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Whooping Cough</mesh_term>
	<mesh_term>Tetanus</mesh_term>
	<mesh_term>Diphtheria</mesh_term>
	<mesh_term>Poliomyelitis</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Aged 30 40 day day first study visit Born full term pregnancy ( ≥ 37 week ) birth weight ≥ 2.5 kg Informed consent form sign dated parent ( ) legally acceptable representative Participant parent/legally acceptable representative able attend schedule visit comply trial procedure Born know hepatitis B surface antigen ( HBsAg ) seronegative mother ( document laboratory result HBsAg assay maternal blood sample available ) Have receive one document dose Hep B vaccine birth accord national recommendation . Participation 4 week precede trial inclusion plan participation present trial period another clinical trial investigate vaccine , drug , medical device , medical procedure Receipt vaccine 4 week precede trial vaccination ( except Bacille Calmette Guerin ( BCG ) vaccine ) plan receipt vaccine 8 day follow trial vaccination Previous vaccination diphtheria , tetanus , pertussis , poliomyelitis , hepatitis B ( except dose Hep B vaccine give birth ) diseases Haemophilus influenzae type b infection either trial vaccine another vaccine Past current receipt immune globulin , blood bloodderived product plan administration trial Known suspect congenital acquired immunodeficiency ; receipt immunosuppressive therapy , anticancer chemotherapy radiation therapy , since birth ; longterm systemic corticosteroid therapy ( prednisone equivalent 2 consecutive week since birth ) Known personal maternal history Human Immunodeficiency Virus ( HIV ) hepatitis C seropositivity History diphtheria , tetanus , pertussis , poliomyelitis , hepatitis B , Haemophilus influenzae type b infection , confirm either clinically , serologically , microbiologically Known systemic hypersensitivity vaccine component , history lifethreatening reaction vaccine use trial vaccine contain substance Known thrombocytopenia , report parent/legally acceptable representative Bleeding disorder , receipt anticoagulant 3 week precede inclusion , contraindicate intramuscular vaccination In emergency setting , hospitalize involuntarily Chronic illness , opinion investigator , stage might interfere trial conduct completion Moderate severe acute illness/infection ( accord investigator judgment ) day vaccination febrile illness ( temperature ≥ 38.0°C ) . A prospective participant include study condition resolve febrile event subside Identified natural adopt child Investigator employee direct involvement propose study History seizure .</criteria>
	<gender>All</gender>
	<minimum_age>1 Month</minimum_age>
	<maximum_age>6 Months</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>Diphtheria</keyword>
	<keyword>Tetanus</keyword>
	<keyword>Pertussis</keyword>
	<keyword>Haemophilus influenzae type b infection</keyword>
	<keyword>Hepatitis B</keyword>
	<keyword>DTaP-IPV-Hep - PRP-T vaccine</keyword>
</DOC>